LOS ANGELES--(BUSINESS WIRE)--
Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they obtained a Patent for Treating Lactose Intolerance Utilizing Genetically Engineered Bacteria US8,236,297B2. Acquired lactase deficiency is the most common disorder of complex carbohydrate absorption throughout the world, affecting 75% of world population. In the United States 15% of Caucasians, over 50% of Hispanics and over 80% of African-Americans suffer from lactose intolerance.
The present invention relates to genetically engineered bacteria that are able to colonize the mammalian intestine and actively produce mammalian lactase. This lactose-digesting enzyme is stable and active under the conditions normally found in the mammalian small intestine. Experimental subjects colonized with the genetically engineered bacteria show improved ability to digest lactose in dairy foods.
About Celprogen Inc.
Celprogen Inc. is a global Stem Cell Research & Therapeutics company which is developing a proprietary portfolio of unique therapeutics products and life science research tools that includes genetic engineering technologies, stem cell technologies for regenerative medicine, as well as bio-engineering products for tissue & organ transplants. Headquartered in San Pedro, California, Celprogen is committed to the research, development, and manufacture of quality Stem Cell, Cancer Stem Cell and Primary Cell Culture products to serve our global community. Additional information about Celprogen is available at http://www.celprogen.com.
See the article here:
Celprogen Obtained US Patent (US8,236,297B2) Method of Treating Lactose Intolerance Utilizing Genetically Engineered ...